PE20060418A1 - Anticuerpos antagonistas de il-17 - Google Patents

Anticuerpos antagonistas de il-17

Info

Publication number
PE20060418A1
PE20060418A1 PE2005000902A PE2005000902A PE20060418A1 PE 20060418 A1 PE20060418 A1 PE 20060418A1 PE 2005000902 A PE2005000902 A PE 2005000902A PE 2005000902 A PE2005000902 A PE 2005000902A PE 20060418 A1 PE20060418 A1 PE 20060418A1
Authority
PE
Peru
Prior art keywords
seq
refers
cdr2
cdr3
variable domain
Prior art date
Application number
PE2005000902A
Other languages
English (en)
Spanish (es)
Inventor
Padova Franco E Di
Hermann Gram
Margit Jeschke
Den Berg Wim Van
Jean-Michel Rondeau
Hans Hofstetter
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32982602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060418(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20060418A1 publication Critical patent/PE20060418A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PE2005000902A 2004-08-05 2005-08-03 Anticuerpos antagonistas de il-17 PE20060418A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0417487.6A GB0417487D0 (en) 2004-08-05 2004-08-05 Organic compound

Publications (1)

Publication Number Publication Date
PE20060418A1 true PE20060418A1 (es) 2006-06-15

Family

ID=32982602

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000902A PE20060418A1 (es) 2004-08-05 2005-08-03 Anticuerpos antagonistas de il-17

Country Status (40)

Country Link
US (9) US7807155B2 (show.php)
EP (5) EP1776142B9 (show.php)
JP (1) JP4682200B2 (show.php)
KR (2) KR100852523B1 (show.php)
CN (1) CN101001645B (show.php)
AR (1) AR050200A1 (show.php)
AT (1) ATE517924T1 (show.php)
AU (2) AU2005268857C1 (show.php)
BE (1) BE2015C041I2 (show.php)
BR (3) BR122018075556B1 (show.php)
CA (1) CA2573586C (show.php)
CY (6) CY1111963T1 (show.php)
DK (4) DK1776142T6 (show.php)
EC (1) ECSP077198A (show.php)
ES (4) ES2677245T3 (show.php)
FR (1) FR15C0048I2 (show.php)
GB (1) GB0417487D0 (show.php)
HK (1) HK1256639A1 (show.php)
HR (3) HRP20110758T4 (show.php)
HU (4) HUE038187T2 (show.php)
IL (1) IL180717A (show.php)
LT (3) LT2902039T (show.php)
LU (2) LU92768I2 (show.php)
MA (1) MA28982B1 (show.php)
MX (1) MX2007001338A (show.php)
MY (1) MY144925A (show.php)
NL (1) NL300749I2 (show.php)
NO (9) NO336279B1 (show.php)
NZ (1) NZ552658A (show.php)
PE (1) PE20060418A1 (show.php)
PL (4) PL2364729T6 (show.php)
PT (4) PT1776142E (show.php)
RU (2) RU2426741C3 (show.php)
SG (1) SG155186A1 (show.php)
SI (4) SI2902039T1 (show.php)
TN (1) TNSN07034A1 (show.php)
TR (1) TR201808057T4 (show.php)
TW (1) TWI359153B (show.php)
WO (1) WO2006013107A1 (show.php)
ZA (1) ZA200700242B (show.php)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
JP2009507023A (ja) * 2005-09-01 2009-02-19 シェーリング コーポレイション 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用
HRP20120606T4 (hr) * 2005-12-13 2020-08-07 Eli Lilly And Company Protutijela protiv il-17
EP3441403A1 (en) 2005-12-20 2019-02-13 SBI Biotech Co., Ltd. Anti-ilt7 antibody
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
KR20080099290A (ko) * 2006-01-31 2008-11-12 노파르티스 아게 암 치료용 ｉｌ-17 길항 항체
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
CA2660463C (en) * 2006-08-11 2013-07-16 Schering Corporation Antibodies to il-17a
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
EP2417974A1 (en) 2007-02-28 2012-02-15 Schering Corporation Combination therapy for treatment of immune disorders
CA2993565C (en) 2007-05-29 2019-04-02 Novartis Ag New indications for anti-il-1-beta therapy
JP5237366B2 (ja) * 2007-06-20 2013-07-17 メルク・シャープ・アンド・ドーム・コーポレーション 炎症性関節疾患に対する抗ｉｌ−１７ａ治療のための関節破壊のバイオマーカー
JP2010534664A (ja) * 2007-07-23 2010-11-11 セントコア・オーソ・バイオテツク・インコーポレーテツド Ｉｌ−１７拮抗薬を用いた線維症関連疾患治療の方法及び組成物
US20110195509A1 (en) * 2007-09-06 2011-08-11 Drew Pardoll Treatment of th17-mediated autoimmune disease via inhibition of stat 3
WO2009072802A2 (en) * 2007-12-03 2009-06-11 Amorepacific Corporation Composition for slimming
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2009089036A2 (en) 2008-01-09 2009-07-16 Schepens Eye Research Institute Therapeutic compositions for treatment of ocular inflammatory disorders
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CN104338136A (zh) * 2008-04-29 2015-02-11 安进研发（慕尼黑）股份有限公司 用于治疗的gm-csf和il-17抑制剂
KR20170023209A (ko) 2008-05-05 2017-03-02 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
MX2010013236A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
TW201008580A (en) 2008-06-03 2010-03-01 Abbott Lab Dual variable domain immunoglobulin and uses thereof
KR20110031369A (ko) 2008-07-08 2011-03-25 아보트 러보러터리즈 프로스타글란딘 ｅ2 이원 가변 도메인 면역글로불린 및 이의 용도
CN102164959A (zh) * 2008-09-29 2011-08-24 罗氏格黎卡特股份公司 针对人il17的抗体及其应用
PE20121094A1 (es) 2009-03-05 2012-09-13 Abbvie Inc Proteinas de union a il-17
DK2424895T3 (en) * 2009-04-27 2017-12-18 Novartis Ag Compositions and Methods for Increasing Muscle Growth
CN102458437B (zh) 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
US8586714B2 (en) 2009-09-01 2013-11-19 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
EP2485763A4 (en) * 2009-10-10 2013-10-30 Univ Leland Stanford Junior CYTOKINE COMPOSITIONS OF THE IL-17 FAMILY AND ITS USES
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
NZ599737A (en) 2009-10-30 2015-02-27 Janssen Biotech Inc Il-17a antagonists
PH12012502272A1 (en) 2010-05-20 2017-07-26 Ablynx Nv Biological materials related to her3
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
RU2595385C2 (ru) * 2010-08-05 2016-08-27 Анаптисбайо, Инк. Антитела, направленные против il-17
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG187938A1 (en) 2010-08-26 2013-04-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
SMT202200321T1 (it) 2010-10-01 2022-09-14 Modernatx Inc Acidi ribonucleici contenenti n1-metil-pseudouracili e loro usi
AU2011311482B2 (en) * 2010-10-08 2014-05-29 Novartis Ag Methods of treating psoriasis using IL-17 antagonists
AU2014259523B2 (en) * 2010-11-05 2016-02-04 Novartis Ag Methods of treating psoriatic arthritis using IL-17 antagonists
JP2014503482A (ja) * 2010-11-05 2014-02-13 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法
AR084234A1 (es) 2010-12-13 2013-05-02 Novartis Ag Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
JP5947041B2 (ja) * 2011-01-07 2016-07-06 第一三共ヘルスケア株式会社 安全なｉｌ−１７産生抑制剤
EP2663869A1 (en) * 2011-01-13 2013-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of having a cardiovascular event in a subject
EP3219728A1 (en) 2011-01-14 2017-09-20 UCB Biopharma SPRL Antibody molecules which bind il-17a and il-17f
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
EP2691411B1 (en) 2011-03-29 2020-02-26 GlaxoSmithKline LLC Buffer system for protein purification
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
CN104011223A (zh) * 2011-11-21 2014-08-27 诺华股份有限公司 使用il-17拮抗剂及psa应答或非应答等位基因治疗银屑病性关节炎(psa)的方法
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
EP2791169B1 (en) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
UY34558A (es) 2011-12-30 2013-07-31 Abbvie Inc Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
WO2013116682A1 (en) 2012-02-02 2013-08-08 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP2015513913A (ja) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ポリヌクレオチド
PE20142422A1 (es) 2012-04-05 2015-01-21 Hoffmann La Roche Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos
BR112014025768A2 (pt) 2012-04-20 2017-07-04 Novartis Ag métodos de tratamento de espondilite anquilosante usando antagonistas de il-17
CN104884473B (zh) 2012-05-22 2019-12-03 百时美施贵宝公司 Il-17a/f il-23双特异性抗体及其应用
EP2914289B1 (en) 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
TW202037609A (zh) 2012-11-01 2020-10-16 美商艾伯維有限公司 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
WO2014107737A2 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
CA3185317A1 (en) 2013-02-08 2014-08-14 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
CA2904448A1 (en) 2013-03-15 2014-09-18 Tariq Ghayur Dual specific binding proteins directed against il-1.beta. and/or il-17
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014155278A2 (en) * 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
JP6255099B2 (ja) 2013-08-15 2017-12-27 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
EP3039039B1 (en) 2013-08-30 2021-03-10 Takeda GmbH Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
EP3072905B1 (en) * 2013-11-18 2020-08-19 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-17a binding agent and uses thereof
EP3101035B1 (en) * 2014-01-28 2021-10-06 Beijing Hanmi Pharmaceutical Co., Ltd. Bifunctional fusion protein, preparation method therefor, and use thereof
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
EP3191120B1 (en) 2014-09-10 2024-04-10 Novartis Ag Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
RU2609627C2 (ru) 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
KR102513870B1 (ko) 2014-10-14 2023-03-23 노파르티스 아게 Pd-l1에 대한 항체 분자 및 그의 용도
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
EP3245224B1 (en) 2015-01-12 2020-07-15 Affibody AB Il-17a-binding polypeptides
JP2018506275A (ja) 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
CN108251431B (zh) 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EA201792527A1 (ru) 2015-07-16 2018-06-29 Эли Лилли Энд Компани Лечение зуда
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
JP6858766B2 (ja) 2015-10-19 2021-04-14 ノバルティス アーゲー インターロイキン１７（ｉｌ−１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
CN114874322A (zh) 2016-03-10 2022-08-09 维埃拉生物股份有限公司 Ilt7结合分子及其使用方法
HRP20241557T1 (hr) 2016-03-10 2025-05-23 Acceleron Pharma Inc. Proteini koji vezuju receptor aktivina tipa 2 i njihova uporaba
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
FR3051673B1 (fr) * 2016-05-24 2018-06-22 Assistance Publique - Hopitaux De Paris Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
ES2992409T3 (es) 2016-07-19 2024-12-12 Novartis Ag Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17
EP3514176B1 (en) 2016-09-14 2021-12-15 Beijing Hanmi Pharmaceutical Co., Ltd. Antibody specifically binding to il-17a and functional fragment thereof
JP2019505516A (ja) 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
PE20191548A1 (es) 2017-02-10 2019-10-24 Genentech Inc Anticuerpos contra triptasa, composiciones de estos y usos de estos
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
TW201842933A (zh) 2017-05-05 2018-12-16 瑞士商諾華公司 使用il-17拮抗劑選擇性治療氣喘的方法
CN108359011B (zh) 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 靶向于白介素17a的抗体、其制备方法和应用
EP3703819A1 (en) 2017-11-02 2020-09-09 Novartis AG Method of treating tendinopathy using interleukin-17 (il-17) antagonists
US20200277369A1 (en) 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
US20200371091A1 (en) 2017-11-30 2020-11-26 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
WO2019191563A1 (en) * 2018-03-29 2019-10-03 Remd Biotherapeutics, Inc. Treatment of autoimmune and inflammatory disorders using antibodies that bind interleukin-17a (il-17a)
CN110551215A (zh) * 2018-05-30 2019-12-10 中山康方生物医药有限公司 抗白细胞介素-17a抗体、其药物组合物及其用途
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
US12134644B2 (en) 2018-07-31 2024-11-05 Weiqun SHEN Anti-IL-17A antibodies and use thereof
EP3856772A1 (en) 2018-09-25 2021-08-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
KR20210122243A (ko) 2019-01-31 2021-10-08 누맙 세러퓨틱스 아게 ＴＮＦα 및 ＩＬ-17Ａ에 대한 특이성을 가지는 다중 특이적 항체, ＩＬ-17Ａ를 표적화하는 항체, 그리고 이의 사용 방법
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
UA128098C2 (uk) 2019-02-18 2024-04-03 Елі Ліллі Енд Компані Водна фармацевтична композиція антитіла проти il-17a
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
EP3976032A4 (en) * 2019-05-31 2023-06-14 Figene, LLC SIMULTANEOUS ACTIVATION OF REGENERATIVE AND TOLEROGENIC PROCESSES BY COMPOSITIONS BASED ON FIBROBLASTS IN THE TREATMENT OF MULTIPLE SCLEROSIS
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
EP4036113B1 (en) 2019-07-26 2025-11-19 Sinocelltech Ltd. Humanized anti-il17a antibody and use thereof
CN114127108A (zh) 2019-07-30 2022-03-01 江苏恒瑞医药股份有限公司 Il-17拮抗剂治疗自身免疫疾病的方法
US12497449B2 (en) 2019-09-20 2025-12-16 Novartis Ag Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonists
WO2021060425A1 (ja) * 2019-09-25 2021-04-01 国立大学法人東京大学 全身性強皮症治療用医薬組成物
CA3156167A1 (en) 2019-09-30 2021-04-08 Janssen Pharmaceutica Nv Compositions and methods for an il-17 target engagement assay with large molecule modulators
AR121183A1 (es) 2019-11-19 2022-04-27 Novartis Ag Métodos de tratamiento de la nefritis lúpica con antagonistas de interleucina-17 (il-17)
JP2023504679A (ja) 2019-12-06 2023-02-06 ノバルティス アーゲー インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して扁平苔癬を治療する方法
CN111040035B (zh) * 2019-12-31 2022-05-24 南京融捷康生物科技有限公司 针对il-17ra蛋白的抗体及其制备方法和应用
BR112022026273A2 (pt) 2020-06-23 2023-01-17 Novartis Ag Métodos de tratamento da doença ocular da tireoide e orbitopatia de graves usando antagonistas de interleucina-17 (il-17)
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17
KR20230104651A (ko) 2020-11-06 2023-07-10 노파르티스 아게 Cd19 결합 분자 및 이의 용도
EP4255927A1 (en) 2020-12-02 2023-10-11 Fresenius Kabi Deutschland GmbH Methods of selectively reducing antibodies
KR20230124971A (ko) 2020-12-22 2023-08-28 노파르티스 아게 세포 배양 중 분비된 재조합 발현 단백질에서 시스테인잔기의 산화 수준을 감소시키는 방법
JP2025513513A (ja) 2022-04-25 2025-04-24 ノバルティス アーゲー Ｉｌ－１７阻害剤の結晶形態
KR20250011951A (ko) 2022-05-16 2025-01-22 노파르티스 아게 인터루킨-17 (il-17) 길항제를 사용한 거대 세포 동맥염의 치료 방법
IL316872A (en) 2022-05-18 2025-01-01 Novartis Ag Methods for selective treatment of tendinopathy using interleukin-17 (IL-17) antagonists
EP4654999A1 (en) 2023-01-27 2025-12-03 Fresenius Kabi Deutschland GmbH Biopharmaceutical composition
EP4406553A1 (en) 2023-01-27 2024-07-31 Fresenius Kabi Deutschland GmbH Stable secukinumab biopharmaceutical composition
KR20240141083A (ko) 2023-03-17 2024-09-25 (주)셀트리온 안정한 약제학적 제제 및 완제의약품의 제조공정
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
CN117843778B (zh) * 2023-12-21 2024-07-26 北京贝来药业有限公司 针对白介素家族成员的新型纳米抗体及其产品和应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
GB202407664D0 (en) 2024-05-30 2024-07-17 Fresenius Kabi Deutschland Gmbh Post-translational control of recombiant proteins
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6274711B1 (en) 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
EP0817847B2 (en) 1995-03-23 2009-09-09 Immunex Corporation Il-17 receptor
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
ATE295414T1 (de) 1995-07-19 2005-05-15 Inst Genetics Llc Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
ES2181915T3 (es) 1995-10-27 2003-03-01 Schering Corp Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.
JP2001506982A (ja) 1996-11-27 2001-05-29 イミュネックス・コーポレーション 一酸化窒素産生の制御法
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
EP1015488B1 (en) 1997-09-17 2009-09-09 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
CA2309604C (en) 1997-11-10 2010-01-12 Cytimmune Sciences, Inc. Compositions and methods for targeted delivery of factors
US6562578B1 (en) 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
WO1999032632A1 (en) 1997-12-19 1999-07-01 Millennium Pharmaceuticals, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
JP2003502006A (ja) 1998-01-09 2003-01-21 イミュネックス・コーポレーション Ｉｌ−１７ｒｈｄｎａ及びポリペプチド
WO1999035267A1 (en) 1998-01-09 1999-07-15 Immunex Corporation Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
WO1999041368A2 (en) 1998-02-11 1999-08-19 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
EP2333069A3 (en) 1998-05-15 2011-09-14 Genentech, Inc. Therapeutic uses of IL-17 homologous polypeptides
EP1897948A1 (en) 1998-09-17 2008-03-12 ZymoGenetics, Inc. Mammalian transforming growth factor beta 9
AU6277799A (en) 1998-10-02 2000-04-26 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and usesthereof
JP2000186046A (ja) * 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
AU1071200A (en) 1998-10-19 2000-05-08 Biotech Australia Pty Limited Systems for oral delivery
DE29820466U1 (de) 1998-11-16 1999-04-08 Reutter, Werner, Prof. Dr.med., 14195 Berlin Rekombinante Glycoproteine und sie enthaltende Arzneimittel
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
AR022237A1 (es) 1999-01-11 2002-09-04 Schering Corp Citoquinas mamiferas purificadas; reactivos y metodos relacionados
SI1141297T1 (sl) 1999-01-11 2010-01-29 Schering Corp Interlevkinu-17 sorodni sesalski citokini, polinukleotidi, ki jih kodirajo uporabe
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
ES2313883T3 (es) 1999-02-12 2009-03-16 The Scripps Research Institute Procedimientos para el tratamiento de tumores y metastasis utilizando una combinacion de terapias antiangiogenicas e inmunoterapias.
US6036128A (en) 1999-05-17 2000-03-14 Common Ground Recycling, Inc. Tire shredding machine and method of using the same
EP1053751A1 (en) * 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
AU6677000A (en) 1999-08-27 2001-03-26 University Health Network Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen
JP2001086046A (ja) * 1999-09-09 2001-03-30 Nec Corp カメラ付き携帯電話装置
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
KR20120053525A (ko) 2000-06-16 2012-05-25 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
US20060083713A1 (en) 2000-10-13 2006-04-20 Eli Lilly And Company Methods of using a human il-17 related polypeptide to treat disease
AU2002246746B2 (en) * 2000-10-18 2007-05-31 Kirin-Amgen, Inc. Methods for treating rheumatoid arthritis using il-17 antagonists
CA2435151A1 (en) 2001-01-25 2002-12-27 Zymogenetics, Inc. Method for treating psoriasis
EP2009027B1 (en) * 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
CA2467521A1 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
PL376536A1 (pl) 2002-08-28 2006-01-09 Immunex Corporation Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego
CA2526398C (en) * 2003-05-21 2014-07-15 Medarex, Inc. Human monoclonal antibodies against bacillus anthracis protective antigen
US20070269428A1 (en) 2003-11-21 2007-11-22 Celltech R&D Limited Method for the Treatment of Multiple Sclerosis by Inhibiting Il-17 Activity
CN1993480A (zh) 2004-05-03 2007-07-04 先灵公司 Il－17表达预测皮肤炎症的用途；治疗方法
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
JP2009507023A (ja) 2005-09-01 2009-02-19 シェーリング コーポレイション 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用

Also Published As

Publication number Publication date
JP2008507988A (ja) 2008-03-21
NO336279B1 (no) 2015-07-06
EP2902039B1 (en) 2018-04-11
ES2367440T7 (es) 2015-07-14
NO20151787L (no) 2006-02-06
LTPA2015029I1 (lt) 2022-07-11
NO2016017I1 (no) 2016-08-23
BRPI0513078B8 (pt) 2019-08-27
RU2426741C3 (ru) 2017-11-15
RU2426741C2 (ru) 2011-08-20
HRP20110758T4 (hr) 2015-07-31
US20150152178A1 (en) 2015-06-04
US9765140B2 (en) 2017-09-19
SI1776142T1 (sl) 2011-11-30
US20190270804A1 (en) 2019-09-05
NL300749I2 (nl) 2017-11-02
NO2015023I1 (no) 2015-11-02
DK2364729T6 (en) 2015-07-06
US20250122277A1 (en) 2025-04-17
HUS1800040I1 (hu) 2018-11-28
EP3409288A1 (en) 2018-12-05
AU2005268857B2 (en) 2010-01-28
CY2015030I1 (el) 2015-11-04
PL2902039T3 (pl) 2018-09-28
US20120107325A1 (en) 2012-05-03
US20170355762A1 (en) 2017-12-14
EP2366405B1 (en) 2015-02-25
EP2366405A2 (en) 2011-09-21
NO20150065L (no) 2007-03-30
BRPI0513078B1 (pt) 2019-02-19
MX2007001338A (es) 2008-03-11
NO20070985L (no) 2007-03-30
CN101001645A (zh) 2007-07-18
US20140079719A1 (en) 2014-03-20
NO337129B1 (no) 2016-01-25
TR201808057T4 (tr) 2018-06-21
ES2367440T9 (es) 2021-04-28
PL1776142T6 (pl) 2016-06-30
PT2366405E (pt) 2015-06-30
TW200617025A (en) 2006-06-01
ES2487533T3 (es) 2014-08-21
PL2366405T3 (pl) 2015-08-31
SI2902039T1 (en) 2018-07-31
HK1256639A1 (en) 2019-09-27
GB0417487D0 (en) 2004-09-08
FR15C0048I1 (fr) 2015-08-28
LTPA2018515I1 (lt) 2018-10-25
US8617552B2 (en) 2013-12-31
ES2677245T3 (es) 2018-07-31
PT2364729E (pt) 2014-09-01
CA2573586C (en) 2013-06-25
DK1776142T6 (en) 2015-07-06
HK1101277A1 (en) 2007-10-12
DK1776142T3 (da) 2011-10-31
AU2005268857B8 (en) 2010-05-27
HUS1500037I1 (hu) 2017-10-30
EP2364729B1 (en) 2014-05-14
NO341384B1 (no) 2017-10-30
EP1776142B9 (en) 2016-09-07
EP2902039A1 (en) 2015-08-05
AU2010201689B2 (en) 2011-09-29
KR20070036166A (ko) 2007-04-02
PL1776142T3 (pl) 2011-12-30
KR100852523B1 (ko) 2008-08-14
AU2010201689A1 (en) 2010-05-20
EP2364729A3 (en) 2012-01-18
EP2364729A2 (en) 2011-09-14
PT2902039T (pt) 2018-07-17
NO2022026I1 (no) 2022-06-24
RU2007108067A (ru) 2008-09-10
US20100215666A1 (en) 2010-08-26
RU2011113153A (ru) 2012-10-20
CY2018027I2 (el) 2020-05-29
BR122018075556B1 (pt) 2022-10-18
NO2015023I2 (no) 2015-10-26
AU2005268857A1 (en) 2006-02-09
HRP20150480T1 (hr) 2015-07-17
CY1116256T1 (el) 2017-02-08
LU92768I2 (fr) 2015-11-03
EP2364729B3 (en) 2015-06-24
PL2364729T6 (pl) 2016-06-30
DK2366405T3 (en) 2015-05-11
US20090280131A1 (en) 2009-11-12
EP1776142B1 (en) 2011-07-27
US8119131B2 (en) 2012-02-21
US7807155B2 (en) 2010-10-05
WO2006013107A1 (en) 2006-02-09
SI2366405T1 (sl) 2015-07-31
EP1776142A1 (en) 2007-04-25
FR15C0048I2 (fr) 2015-11-20
SI2364729T1 (sl) 2014-08-29
TNSN07034A1 (en) 2008-06-02
PT1776142E (pt) 2011-10-06
AR050200A1 (es) 2006-10-04
CA2573586A1 (en) 2006-02-09
ES2536228T3 (es) 2015-05-21
BRPI0513078C1 (pt) 2021-05-25
EP2366405A3 (en) 2012-01-18
ES2367440T3 (es) 2011-11-03
PL2364729T3 (pl) 2014-10-31
NO348010B1 (no) 2024-06-17
HRP20110758T1 (en) 2011-11-30
NO337286B1 (no) 2016-02-29
DK2902039T3 (en) 2018-07-16
AU2005268857C1 (en) 2012-01-19
BRPI0513078A (pt) 2008-04-22
ECSP077198A (es) 2007-02-28
DK2364729T3 (da) 2014-07-21
HK1207559A1 (en) 2016-02-05
ZA200700242B (en) 2008-08-27
JP4682200B2 (ja) 2011-05-11
PL1776142T4 (pl) 2018-04-30
HRP20181069T1 (hr) 2018-09-07
IL180717A (en) 2012-07-31
LTC1776142I2 (lt) 2022-07-11
NZ552658A (en) 2009-11-27
CY2018027I1 (el) 2020-05-29
US10344084B2 (en) 2019-07-09
KR100852523B9 (ko) 2025-03-28
NO20150064L (no) 2007-03-30
BE2015C041I2 (show.php) 2024-10-08
NO20171697A1 (no) 2007-03-30
CY1115444T1 (el) 2017-01-04
HUE038187T2 (hu) 2018-10-29
CY2015030I2 (el) 2017-11-14
LT2902039T (lt) 2018-06-25
KR20080029018A (ko) 2008-04-02
ES2487533T7 (es) 2015-07-14
BR122017009404B1 (pt) 2022-02-22
CY1111963T1 (el) 2015-11-04
LUC00088I2 (show.php) 2018-12-17
HUE025815T2 (en) 2016-04-28
MY144925A (en) 2011-11-30
IL180717A0 (en) 2007-06-03
MA28982B1 (fr) 2007-11-01
TWI359153B (en) 2012-03-01
EP1776142B3 (en) 2015-06-24
NO2018007I1 (no) 2018-02-14
CN101001645B (zh) 2012-09-05
ATE517924T1 (de) 2011-08-15
CY1120723T1 (el) 2019-12-11
SG155186A1 (en) 2009-09-30
US20230235038A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
PE20060418A1 (es) Anticuerpos antagonistas de il-17
PE20130159A1 (es) Anticuerpos anti-cd40
PE20140633A1 (es) Anticuerpos neutralizadores anti-ccl20
PE20081478A1 (es) Anticuerpos cd44
PE20120211A1 (es) Anticuerpos que tienen especificidad por ox40 humana
PE20090689A1 (es) Anticuerpos del antagonista ox40 y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
PE20191102A1 (es) Anticuerpos anti-pd-1 y sus usos
PE20180499A1 (es) Anticuerpos de union a tau
PE20120815A1 (es) Anticuerpos anti il-17f y metodos de uso de los mismos
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
PE20201255A1 (es) Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos
MY200988A (en) CD3 Binding Antibodies
PE20061324A1 (es) Anticuerpos anti-il-6, composiciones, metodos y usos
PE20020319A1 (es) ANTICUERPOS PARA IL-1ß HUMANA
PE20211293A1 (es) Anticuerpos monoclonales antagonistas contra cd40 y sus usos
PE20141398A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
NZ595235A (en) Compositions and methods for increasing muscle growth
RU2021115081A (ru) Гуманизированные антитела против cd269 (bcma)
PE20140247A1 (es) Anticuerpos anti-cd38
PE20070998A1 (es) Moleculas de anticuerpo que tienen especificidad para la il-6-humana
PE20170912A1 (es) Conjugados de anticuerpo-farmaco
NZ592214A (en) Improved Interleukin-6 receptor antibody molecule
NZ607711A (en) Antibodies directed to her-3 and uses thereof
PE20030104A1 (es) Anticuerpos humanos para cd154
PE20060287A1 (es) INMUNOGLOBULINAS DE UNION SELECTIVA A hOSM

Legal Events

Date Code Title Description
FG Grant, registration